Owlet Q4 Revenue to Rise 24.1% to $25.4M Despite 85.7% EPS Decline
Owlet forecasts fourth-quarter revenue of $25.4 million, up 24.1% year over year, with an EPS loss of $0.13 implying an 85.7% decline. The company has over 85,000 paid subscribers on more than 650,000 active devices and holds FDA clearance for its infant monitoring platform while piloting AI-based sleep coaching features.
1. Earnings Estimates and Historical Performance
Owlet is projected to report fourth-quarter revenue of $25.4 million, a 24.1% increase from year-ago levels, and a loss per share of $0.13, reflecting an 85.7% decline. In the prior quarter, the company exceeded consensus by 113% on EPS and 20.5% on revenue, with top-line growth of 44.6%.
2. Transition to Health Platform and Subscription Growth
The business shift from hardware to a data-enabled pediatric health platform has driven paid subscriber growth past 85,000 and expanded the installed base to over 650,000 active devices. Recurring revenues now form a larger revenue mix, and an upcoming generative AI sleep coaching pilot aims to deepen customer engagement.
3. Regulatory Edge and International Expansion
Owlet remains the only FDA-cleared over-the-counter infant monitoring device, strengthening competitive positioning after recent regulatory actions against unauthorized monitors. Approval in India and early healthcare partnerships are poised to support incremental revenue and long-term optionality.
4. Margin Pressure and Macro Risks
Elevated tariffs and import costs are expected to weigh on gross margins, while cautious consumer spending and post-shutdown uncertainty may dampen holiday sales. Continued investment in software and services could partially offset cost headwinds, but near-term profitability pressures persist.